Tech • AI • Robotics
I tested the new blood test everyone is talking about (LUCIS)
4/10TL;DR
Lucy, a French longevity testing startup, is positioning blood analysis and personalized health plans as a consumer product, reflecting a broader push to turn preventive medicine, biological age tracking and health optimization into a mass market.
KEY POINTS
A consumer offer built around longevity
Lucy sells an annual subscription estimated at €400 to €600, including two blood tests, analysis of roughly 140 biomarkers, and a personalized action plan. The model targets people interested in preventive health rather than waiting for symptoms to trigger a medical checkup. The service is presented as a more accessible alternative to elite longevity routines popularized by figures such as Brian Johnson.
How the testing process works
Customers receive a kit with instructions and sample materials, including containers for urine and saliva collection. Before the blood draw, they are advised to avoid intense exercise for 24 hours, stop eating by around 8 p.m., and arrive fasting, with no alcohol or drugs beforehand. Tests are carried out through partner laboratories rather than dedicated clinics, allowing appointments close to home.
A much heavier blood panel than standard tests
The most striking part of the process is the volume of blood taken. A standard blood test often uses one to three vials, while pregnancy-related screening may require about six. Lucy draws 16 to 18 vials, making the appointment notably longer and more physically demanding, especially for people sensitive to needles or fasting.
Results combine scoring, biological age and flagged risks
Results typically arrive after 10 to 14 days, longer than a routine lab report because of the expanded biomarker analysis. The platform produces a longevity score out of 100, a biological age estimate and a breakdown of areas classified as elevated risk, good health or optimal health. In one case discussed, a 27-year-old user received a biological age of 23, implying aging at roughly 0.85 biological year per chronological year.
Findings can be motivating, but interpretation remains difficult
Biological age is the most engaging metric because it turns health into a measurable benchmark that can be improved over time. The platform also appeals to users who like quantified self-tracking and competition, whether against their previous results or against friends. But the medical terminology can be dense, and first-time users may struggle to understand markers without outside help.
The platform’s weaknesses are clarity and execution
Several frictions stand out: specialized vocabulary, a chatbot seen as too limited for clear explanations, and delays in delivering both lab results and follow-up recommendations. Some results can also be skewed by behavior before testing, such as high-intensity exercise the previous day. That makes compliance with the preparation rules essential if users want reliable comparisons over time.
The action plan is the product’s practical core
About a week after the lab analysis, users receive a structured plan linking biomarker results with questionnaire data on sleep, stress, diet, exercise and mental health. Recommendations may cover sleep quality, fiber intake, omega-3 consumption, cholesterol management or hormone-related issues. The company also encourages users to consult healthcare professionals when a marker suggests a potentially significant problem.
Examples of issues identified
Among the notable signals flagged were elevated morning stress markers and high cholesterol. The cholesterol warning was linked to possible low fiber intake, insufficient omega-3, and potentially hereditary factors. Testosterone levels were reported at 610, above the cited French average range of roughly 400 to 600, though the comparison also highlighted that averages differ by country.
A potential platform play beyond testing
The broader business opportunity may be larger than blood tests alone. If integrated with wearables, medical records, recurring lab work and coaching, a service like Lucy could become a central hub for personal health data. That raises comparisons to Strava for sports or wealth dashboards such as Finary, with blood testing functioning as the acquisition channel before upselling guidance, subscriptions, products or partnerships.
New markets are already visible
Two adjacent opportunities stand out: a similar service for pets, and a longevity-focused fitness app built around proven markers such as grip strength, mobility, leg power and daily movement. Companies like Garmin, Whoop or future consolidators could eventually move into this space through acquisition or direct competition. The main strategic question is whether early players can build enough trust, data depth and user habit before larger platforms enter.
CONCLUSION
Longevity services are moving from niche biohacking into mainstream preventive health, blending biomarker analysis, behavioral coaching and consumer software. The winners may be the companies that make complex health data understandable, actionable and sticky enough to become a daily platform rather than a one-off test.
Explain this